UBS Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $31
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $31 to $33
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $30 to $36
Leerink Partners Maintains Pfizer(PFE.US) With Hold Rating
Moderna Stock Price Target Slashed. It's About Vaccines. -- Barrons.com
Pfizer Analyst Ratings
Cantor Fitzgerald Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $45
Pfizer (PFE) Gets a Buy From Cantor Fitzgerald
Citi Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Pfizer Maintained Neutral on Analyst Transfer at Citi
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Pfizer Analyst Ratings
Hold Recommendation on Pfizer Amid Promising but Early Stage Cancer Cachexia Drug Development
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Mixed Prospects and Uncertainty Lead to Hold Rating for Pfizer Amid COVID-19 Revenue Fluctuations
Goldman Sachs Adjusts Price Target on Pfizer to $32 From $34
Pfizer Price Target Announced at $32.00/Share by Bernstein
Pfizer Analyst Ratings
Pfizer Initiated With a Market Perform at Bernstein